To the Editor: Hui and colleagues must be commended for underscoring that a program with centralisation should be a cornerstone for hepatocellular carcinoma (HCC) surveillance.1 Indeed, with funding for quality assurance, it allows for monitoring of uptake to guarantee effectiveness and equitability. However, their narrative review deserved robust comments.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Hui S, Bell S, Le S, Dev A. Hepatocellular carcinoma surveillance in Australia: current and future perspectives. Med J Aust 2023; 219: 432‐438. https://www.mja.com.au/journal/2023/219/9/hepatocellular‐carcinoma‐surveillance‐australia‐current‐and‐future‐perspectives
- 2. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417‐422.
- 3. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012; 156: 387‐389.
- 4. Braillon A, Nguyen‐Khac E. Hepatocellular carcinoma: a pledge for evidence‐based medicine. Am J Med 2008;121: e7‐e12.
- 5. National Cancer Institute, US National Institutes of Health. Liver (Hepatocellular) cancer screening (PDQ®)–health professional version. https://www.cancer.gov/types/liver/hp/liver‐screening‐pdq#section/all (viewed Nov 2023).
- 6. Lubel JS, Roberts SK, Strasser SI, Shackel N. Australian recommendations for the management of hepatocellular carcinoma. Med J Aust 2021; 215: 334‐334. https://www.mja.com.au/journal/2021/215/7/australian‐recommendations‐management‐hepatocellular‐carcinoma‐0
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.